Vernalis said in late February further acceleration in Tuzistra XR sales were required to meet its guidance, and that given approximately two-thirds of the cough cold season has passed, such acceleration was "unlikely".
Vernalis said it was considering different strategies for US operations as well as strategic options for the group. Plans to reduce cash burn as "well developed" and a more detailed update will be given "in the coming weeks".
It has now confirmed it will consider offers for the whole business, and is to wind down business in the US including the ceasing of promotion of Tuzistra to physicians at the end of the current cold season. The US business is expected to cease operations by the end of September.
Vernalis has also ended efforts to secure a new supply source for its Moxatag treatment, and is in talks to pull out of future cough cold development programmes.
The company also said Chief Executive Ian Garland and Chief Financial Officer David Mackney will both leave their roles in September, once US operations are ended.
A further update will be provided alongside half year results on March 28. Shares were down 0.1% on Thursday at
